Subject(s)
Conservation of Natural Resources , Ecosystem , Environment , Health , United States Government Agencies , Animals , Animals, Wild , Climate , Conservation of Natural Resources/trends , Disasters , Energy-Generating Resources , Forecasting , Geological Phenomena , Geology , Humans , Interdisciplinary Communication , Public Policy , United States , WaterSubject(s)
Ecosystem , Waste Disposal, Fluid/methods , Water Purification/methods , Belgium , Pilot Projects , Seasons , Temperature , Water MovementsABSTRACT
In the present double-blind placebo-controlled study the effect of cisapride on functional dyspepsia was evaluated in patients with and without histological gastritis. Patients with functional dyspepsia and whose symptoms persisted after a 2 week run-in period with antacid treatment were randomized to receive cisapride (10 mg) or matching placebo three times daily for 4 weeks. Symptoms of epigastric pain, bloating, nausea, belching, early satiety and heartburn were graded on a four-point scale based on patients' feedback and diary card recording. A global response was also formulated by the investigators. One hundred and four patients entered the study and 76 completed the trial, comprising 36 patients with histological gastritis and 40 patients without gastritis. Symptom scores in both gastritis and non-gastritis groups were significantly improved by both cisapride and placebo; however, the improvement was not statistically different between the two treatment groups. Cisapride produced a good or better global response in 58% of subjects with histological gastritis and in 53% of subjects without gastritis compared with 47% and 52%, respectively, of patients on placebo; this difference was not statistically significant. Gastric histology did not influence the effect of cisapride on the symptoms of functional dyspepsia.
Subject(s)
Anti-Ulcer Agents/therapeutic use , Dyspepsia/drug therapy , Gastritis/drug therapy , Piperidines/therapeutic use , Adult , Cisapride , Double-Blind Method , Dyspepsia/pathology , Dyspepsia/physiopathology , Female , Gastric Mucosa/pathology , Gastritis/pathology , Gastritis/physiopathology , Humans , Male , Middle AgedABSTRACT
El nuevo mucolítico FLUDIPRONT se investigó en 20 pacientes sufriendo de bronquitis crónica. La satisfacción de los pacientes fue objetivada por las mejoras significantes de la capacidad vital y capacidad absoluta por segundo, reducción (estadísticamente) de la espectoración, mejora del aspecto macroscópico del esputo (estadísticamente) así como la disminución de los componentes en el esputo responsables del agobio de la espectoración. En estudios prolongados, FLUDIPRONT ha sido aplicado en 42 pacientes durante y hasta 90 días. La dosificación fue de 3 por día 15 ml del jarabe de excelente sabor. Excepto 3 interrupciones transitorias a causa de `sequedad traqueal' e indisposición gástrica, no hubo ningún efecto secundario
Subject(s)
Humans , Male , Female , Bronchitis/therapy , Expectorants/therapeutic use , Peru , Smoking/adverse effectsSubject(s)
Hypersensitivity/therapy , Splenectomy , Tissue Extracts/therapeutic use , Animals , Guinea Pigs , Humans , SpleenSubject(s)
Dust , Mollusca/drug effects , Smoking , Animals , Behavior, Animal/drug effects , Cilia/drug effects , Mucus/drug effects , Mucus/metabolismSubject(s)
Bronchitis/drug therapy , Oils, Volatile/administration & dosage , Adult , Aged , Balsams , Clinical Trials as Topic , Female , Humans , Male , Methods , Middle Aged , PlacebosABSTRACT
According to a uniform trial procedure, the broncholytic efficacy of the new beta2-adrenergic 7-(3-[2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, Bronchospasmin) was tested in a total of 21 patients afflicted with airways obstruction in two lungfunction laboratories. The IGV, Ras and SGaw were calculated by bodyplethysmography before and 1,3 and 5 min following of 2 puffs from an aerosol container. Excellent and highly significantly bronchodilation was shown already 1 min post inhalation, which further increased during testing time and with which results of subjective criteria for dyspnoeic changes correspond. The preparation may therefore be recommended for therapy of dyspnoeic attacks in an aerosol form equipped with metering valves.
Subject(s)
Bronchodilator Agents/therapeutic use , Phenethylamines/therapeutic use , Xanthines/therapeutic use , Aerosols , Airway Resistance/drug effects , Dose-Response Relationship, Drug , Female , Humans , Lung Diseases, Obstructive/drug therapy , Lung Diseases, Obstructive/physiopathology , Male , Middle Aged , Plethysmography, Whole Body , Time FactorsSubject(s)
Sputum/analysis , Bronchitis/diagnosis , Chronic Disease , Glycoproteins/analysis , HumansABSTRACT
Sixty-four femoral arteriograms were taken on an outpatient, ambulatory basis in sixty-two patients. There were no complications. It is believed that this method, when applicable, should effect substantial savings in health delivery cost and medical manpower and should facilitate adequate follow-up examinations in certain cases.
